Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON34350
NL-OMON34350CompletedPhase 4

When and in whom to stop etanercept after successful treatment of Juvenile Idiopathic Arthritis - Withdrawal of etanercept after successful treatment

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites50 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
2 to 17 (—)

Inclusion Criteria

  • •- Diagnosis of Juvenile Idiopathic Arthritis (all subtypes) by the International League of Associations of Rheumatology (ILAR) criteria
  • •- On etanercept therapy
  • •- Concomitant therapy allowed are: NSAIDs, low dose MTX (maximum 10 mg/m2), and other medications not related to the treatment of JIA.
  • •- 3 to 18 months in remission according to the criteria of Wallace (i.e. 9 to 24 months of inactive disease)
  • •- Age >=4 and <18 years at start of study
  • •- Written informed consent from parents and patients 12 years and over

Exclusion Criteria

  • •Concomitant medications not allowed are: corticosteroids (including intra-articular corticosteroids up to 6 months prior to inclusion) and other synthetic and biologic DMARDs.

Investigators

Similar Trials

Unknown
Phase 4
Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis
NCT01287715Erasmus Medical Center50
Active, not recruiting
Phase 1
Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA) - DOSERARheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) stateMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2007-006657-63-HUWyeth Pharmaceuticals France186
Active, not recruiting
Not Applicable
Study comparing the effect on disease activity when reducing or discontinuing Etanercept in subjects with Rheumatoid Arthritis (RA) (DOSERA)
EUCTR2007-006657-63-DKPfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom72
Active, not recruiting
Not Applicable
Study comparing the effect on disease activity when reducing or discontinuing Etanercept in subjects with Rheumatoid Arthritis (RA) (DOSERA)
EUCTR2007-006657-63-ISPfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom72
Active, not recruiting
Not Applicable
Study comparing the effect on disease activity when reducing or discontinuing Etanercept in subjects with Rheumatoid Arthritis (RA) (DOSERA)Rheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) stateMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2007-006657-63-FIPfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom72